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Background: To clarify the clinical outcomes of two dose schedule of stereotactic body radiotherapy (SBRT) for
stage I non-small cell lung cancer (NSCLC) using a real-time tumor-tracking radiation therapy (RTRT) system in
single institution.
Methods: Using a superposition algorithm, we administered 48 Gy in 4 fractions at the isocenter in 2005–2006 and
40 Gy in 4 fractions to the 95% volume of PTV in 2007–2010 with a treatment period of 4 to 7 days. Target volume
margins were fixed irrespective of the tumor amplitude.
Results: In total, 109 patients (79 T1N0M0 and 30 T2N0M0). With a median follow-up period of 25 months (range, 4
to 72 months), the 5-year local control rate (LC) was 78% and the 5-year overall survival rate (OS) was 64%. Grade 2,
3, 4, and 5 radiation pneumonitis (RP) was experienced by 15 (13.8%), 3 (2.8%), 0, and 0 patients, respectively. The
mean lung dose (MLD) and the volume of lung receiving 20 Gy (V20) were significantly higher in patients with RP
Grade 2/3 than in those with RP Grade 0/1 (MLD p = 0.002, V20 p = 0.003). There was no correlation between larger
maximum amplitude of marker movement and larger PTV (r = 0.137), MLD (r = 0.046), or V20 (r = 0.158).
Conclusions: SBRT using the RTRT system achieved LC and OS comparable to other SBRT studies with very low
incidence of RP, which was consistent with the small MLD and V20 irrespective of tumor amplitude. For stage I
NSCLC, SBRT using RTRT was suggested to be reliable and effective, especially for patients with large amplitude of
tumor movement.
Keywords: Stereotactic body radiotherapy, Radiation pneumonitis, Non-small cell lung cancer, Real-time
tumor-tracking, Tumor motion, Gated radiotherapyBackground
Stereotactic body radiotherapy (SBRT) with high local
dose has been applied to extra-cranial diseases such as
peripheral stage I non-small cell lung cancer (NSCLC)
and has been reported to provide excellent local control
and survival compatible with surgery [1,2].
Respiratory motion of lung tumors has been one of the
largest uncertainties in the radiotherapy of lung cancers
[3]. Considering respiratory motion, there are several ir-
radiation methods: (i) irradiation with breath coaching* Correspondence: ronimaru@pop.med.hokudai.ac.jp
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reproduction in any medium, provided the orand holding [4-7], (ii) irradiation with respiratory gating
using external surrogates with four-dimensional CT [7],
(iii) immobilization in the stereotactic body frame (Elekta,
Stockholm, Sweden) with an abdominal compression de-
vice to limit respiratory motion during radiotherapy [8,9],
(iv) irradiation using planning CT with a slow scan tech-
nique [10,11], (v) pursuing irradiation with some predic-
tion models [12-17], (vi) and real-time tumor-tracking
radiotherapy (RTRT) system [18].
A prototype RTRT was developed at our institute
in 1999 to increase the precision of irradiation for mo-
ving lung tumors. Real-time tumor-tracking radiotherapy
comprises two different concepts: (i) pursuing irradiation
where the therapeutic beam changes its direction duringtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Abbreviation: NSCLC, non-small cell lung cancer.
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therapeutic beam does not change its direction during
treatment. The prototype RTRT system used the
interrupting irradiation method. We clinically used the
prototype RTRT system in which the linear accelerator
is gated to irradiate the tumor only when the implanted
fiducial marker is within 2 mm from its planned position
[19,20]. We have published a study showing steep dose–
response curve between 40 Gy and 48 Gy in four frac-
tions in one week in patients with stage I NSCLC treated
with RTRT between 2000 and 2005 in our institution
[21]. In that study, we showed that 48Gy at the isocenter
with 5 mm CTV-PTV margin, irrespective of amplitude
of tumor motion, was safe and effective. Since then, dose
calculation software has been upgraded to superposition
algorithm from Clarkson algorithm, resulting in a certain
difference in dose prescription method. The aim of the
present study was to clarify the clinical outcomes of
SBRT for stage I NSCLC using this RTRT system using
dose calculation method with inhomogeneity correction
between 2005 and 2010.
Methods
Patient characteristics
There were 109 patients (79 T1N0M0 and 30 T2N0M0)
who received SBRTfor stage I NSCLC using RTRTsystem at
our institution between June 2005 and November 2010.
Diagnosis of stage I NSCLC was based on whole-body CT
and brain MRI. Of 109 patients, Fluoro-deoxy-glucose
(FDG)-positron emission tomography (PET) was per-
formed in 71 patients (65%). One hundred three patients
had biopsy-proven NSCLC. The other six patients were
biopsy-unproven, but clinically diagnosed as NSCLC
according to evidence of interval progression on at least
two serial CT imaging studies and/or increased FDG up-
take on PET scan. The patient characteristics are given in
Table 1.
SBRT technique
All patients received SBRT to NSCLC using the RTRT
system. The RTRT system has been described in detail
elsewhere [18-20]. In brief, 1.5-mm gold markers were
implanted near the tumor by bronchoscopy. CT scans
were taken with the patients holding their breath at the
end of normal expiration. The gross tumor volume
(GTV) was defined using multi-slice CT taken at the
end of expiration during breath holding. Giraud et al.
reported that CTV margins must be increased to 8 mm
and 6 mm for adenocarcinoma and squamous cell car-
cinoma [22]. Based on their report, we defined the clin-
ical target volume (CTV) as the GTV plus 6 mm for
squamous cell carcinoma, 8 mm for adenocarcinoma,
and 5 mm for others where no appropriate basic litera-
ture had existed. The planning target volume (PTV) wasthe CTV plus a 5-mm margin irrespective of the ampli-
tude of the tumor. The PTV margins were fixed irre-
spective of the tumor amplitude because RTRT is gated
to irradiate the tumor only when the implanted fiducial
marker is within 2 mm from its planned position. There-
fore, the target volume did not increase when the tumor
movement was large, especially in the lower lobe. In our
RTRT system, the irradiated volume depended only on
tumor size. The position of multileaf collimator sets was
usually the PTV plus a 5-mm margin.
Using a superposition algorithm, we administered 48 Gy
in 4 fractions at the isocenter in 2005–2006 (n = 30) and
40 Gy in 4 fractions to the 95% volume of PTV in 2007–
2010 (n = 79) with a treatment period of 4 to 7 days.
Isocenter dose of 40 Gy in 4 fractions to the 95% volume
of PTV was approximately ranged from 45 to 50 Gy.
Figure 1 Kaplan-Meier actuarial overall survival (OS) and local
control (LC) rate.
Figure 2 Kaplan-Meier curve of overall survival (OS) rates for
patients with T1a (n = 47) and T1b or T2 (n = 62). Significant
statistical difference was found (p = 0.01) between the two groups.
Inoue et al. Radiation Oncology 2013, 8:69 Page 3 of 8
http://www.ro-journal.com/content/8/1/69Follow-up after SBRT
Follow-up visits were usually every 3 months after SBRT.
CT scans were usually performed every 3 to 6 months after
SBRT. Distinguishing between residual tumor tissue and
radiation fibrosis was difficult. Local disease recurrence
was considered to have occurred only when enlargement
of the local tumor continued for > 6 months on follow-up
CT scans. FDG-PET and/or histologic confirmation was
recommended when local recurrence was suspected, but
this was not mandatory. Absence of local disease recur-
rence was defined as locally controlled disease.
Ethical considerations
Written informed consent to receive SBRT was obtained
from all patients. This retrospective study was approved
by the ethics committee of Hokkaido university hospital.
This study was performed in accordance with the 1975
Declaration of Helsinki, as revised in 2000.
Statistical analysis
The overall survival (OS) and the local control (LC) rates
were calculated using the Kaplan-Meier method. The log-
rank test was used to calculate the statistical significance
of differences. Multivariate analysis was performed using a
Cox proportional hazards regression model. The diffe-
rence of means was analyzed with Student’s t-test. A value
of p < 0.05 was considered to be statistically significant. R
version 2.14.2 with the survival packages (R project for
statistical computing, Vienna, Austria) was used for statis-
tical analyses.
Results
Local control and survival
The TNM classification and clinical staging were deter-
mined according to the union of international cancer con-
trol (UICC) seventh edition. With a median follow-up
period of 25 months (range, 4 to 72 months), the 3-year
and 5-year local control rate (LC) was 81% (95% confi-
dence interval (CI), 73-91%) and 78% (95% confidence
interval (CI), 68-90%), respectively. The 3-year and 5-year
overall survival rate (OS) was 68% (95% CI, 57-80%) and
64% (95% CI, 53-78%), respectively (Figure 1). In patients
with T1a (tumor diameter ≤ 20 mm), the 3-year and 5-
year LC was 92% (95% CI, 83-100%) and 83% (95% CI, 67-
100%), and the 3-year and 5-year OS was 83% (95% CI,
70-98%) and 75% (95% CI, 58-97%). The OS in patients
with T1a was significantly better compared with 56% (95%
CI, 42-74%) for those with T1b or T2 (tumor diameter >
20 mm) (Figure 2). Univariate analysis showed gender and
FDG-PET before SBRT to be prognostic factors in LC and
tumor size in OS (Table 2). There was no statistical signifi-
cant difference in OS between patients who underwent
FDG-PET before SBRT and those who did not. No statisti-
cally significant difference was observed in OS betweenpatients with pathological diagnosis and those without it.
There was no statistically significant difference in LC and
OS between patients treated with 48 Gy in 4 fractions at
isocenter and those with 40 Gy in 4 fractions to the 95%
volume of PTV. Multivariate analysis demonstrated that
no variable remained as a prognostic factor for LC and
only the tumor diameter ( ≤ / > 2 cm) was a significant
prognostic factor for OS (p = 0.03) (Table 3).
Toxicities
Adverse effects were graded according to the Common
Toxicity Criteria for Adverse Events, version 3.0. Grade 2,
3, 4, and 5 radiation pneumonitis (RP) was experienced by





Lower lobe vs. others 0.25 0.16
Gender
Female vs. others 0.02* 0.66
T stage
T1a vs. others 0.06 0.01*
Primary histology
Adenocarcinoma vs. others 0.16 0.53
Maximum amplitude of marker movement
≥ 3 cm vs. < 3 cm 0.06 0.16
FDG-PET before SBRT (n)
yes vs. no 0.03* 0.30
Dose prescription (n)
48Gy/4fr at isocenter vs. 40Gy/4fr to
the 95% volume of PTV
0.35 0.38
*, significant (p < 0.05).
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mean lung dose (MLD) (of lung volume minus PTV) was
4.0 ± 1.4 Gy in total. MLD was 4.8 ± 1.6 Gy in patients
with RP Grade 2/3, compared with 3.8 ± 1.3 Gy in those
with RP Grade 0/1. The volume of lung receiving 20 Gy
(V20) (of lung volume minus PTV) was 5.8 ± 2.3% in total.
V20 was 7.6 ± 3.3% in patients with RP Grade 2/3, com-
pared with 5.4 ± 2.6% in those with RP Grade 0/1, respec-
tively. MLD and V20 were significantly higher in patients
with RP Grade 2/3 than in those with RP Grade 0/1
(MLD p = 0.002, V20 p = 0.003). There was a strong cor-
relation between larger PTV and larger MLD (r = 0.535,
p < 0.001) and V20 (r = 0.627, p < 0.001) (Figure 3). There
was no significant difference between the patients with
tumor at lower lobe and those with tumor at other lobes
in the MLD, V20, and the incidence of Grade 2 or higher
RP. Grade 2 intercostal neuralgia occurred in 6 patients





Female vs. others 0.05 0.84
T stage
T1a vs. others 0.25 0.03*
Maximum amplitude of the marker movement
≥ 3 cm vs. < 3 cm 0.28 0.53
*, significant (p < 0.05).patient; he had experienced Grade 3 RP after SBRT for the
T1b tumor at the upper lobe. RP was relieved by intraven-
ous infusion of corticosteroids; however, his case was com-
plicated by cytomegalovirus pneumonia, which caused his
death. This infectious pneumonia may be produced due to
immunosuppression caused by steroid therapy; therefore
this might be a treatment-related death. No other adverse
effects of Grade 2 or greater were observed.
Insertion of the gold markers by bronchoscopy
No complications were occurred when gold markers were
implanted near the tumor by bronchoscopy. No inter-
fractional migrations of gold markers were occurred.
Amplitude of respiratory tumor motion
The mean of maximum amplitude of the marker move-
ment of the lower lobe was 27.2 ± 13.8 mm, which was
significantly greater than that of the upper lobe (11.3 ±
9.9 mm, p < 0.001). There was no significant difference be-
tween the lower lobe and other lobes in the 5-year LC and
OS (Table 2). There was no correlation between larger
maximum amplitude of marker movement and larger PTV
(r = 0.137), MLD (r = 0.046), or V20 (r = 0.158) (Figure 4).
Discussion
Breath coaching and holding using stereotactic body
frame has been used as a simple method for SBRT with-
out gating of radiotherapy [6]. However, the effectiveness
of visual coaching for tumor localization is still debat-
able, because of the variations in observers, lengths of
observation times, and reproducibility [6,23,24]. Four-
dimensional CT with a respiratory gating system using
external surrogates has been expected to be useful for
respiratory gating. The combination of external surro-
gates and internal observation with simple prediction
models was suggested to reduce the residual motion of
the tumor in a simulation study [25]. However, the four-
dimensional CT images are all vulnerable to problems
relating to the lack of correlation between external sur-
rogates and internal tumor positions during breathing
[26-28]. Immobilization in the stereotactic body frame
with an abdominal compression device has been used
widely [8,9]; however, internal stabilization of tumor lo-
cation is not certain yet. Planning CT with a slow scan
technique can visualize a major part of the trajectory of
the tumor by scanning each slice for a time longer than
the respiratory cycle [10,11]. With this method, internal
target volume can be quite large when the tumor move-
ment is large. Tracking irradiation dynamically pursuing
the target with some prediction models has been deve-
loped recently bus is still having uncertainty in the mo-
deling of respiratory motion of the tumor [12-17].
The RTRT system potentially resolves these problems
described above. With implantation of internal fiducial
Figure 3 (a) Correlation with planning target volume (PTV) and mean lung dose (MLD), (b) Correlation with PTV and the volume of
lung receiving 20 Gy (V20).
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ternal fiducial markers and internal tumor positions
during breathing is more reliable than in the case of exter-
nal surrogates. Even in the patients with large tumor
movement, the target volume margins can be always fixed
irrespective of the tumor amplitude. Therefore, target vol-
ume does not increase even when the tumor with large
movement, which often occurs especially in the lower
lobe. Irradiated volume depended only on tumor size
using RTRT. Thus, RTRT has potential to reduce the inci-
dence of adverse effect for lung without compromising
tumor control comparing other SBRT technology. How-
ever, migration of fiducial markers in lung is the potential
risk to induce systematic error resulting in higher local re-
lapse rate if we do not take enough care at the daily set-up
of the patient [29]. These theoretical advantage and poten-
tial disadvantage of SBRT using RTRT system and internal
fiducial markers has been debatable.Figure 4 (a) Correlation with maximum amplitude of marker moveme
maximum amplitude of marker movement and mean lung dose (MLD
and the volume of lung receiving 20 Gy (V20).Insertion of gold markers by bronchoscope is essential
for RTRT. Pneumothorax and/or bleeding sometimes
occur in trans-bronchial biopsy (TBB) by bronchoscope;
however insertion of the gold markers by bronchoscope
is much safer than TBB. Pneumothorax and/or bleeding
rarely occur in insertion of gold markers by broncho-
scope. Imura et al. also reported that markers dropped
within the first week after insertion at a high rate and at
a much lower rate 1 week after insertion [29]. We usu-
ally start RTRT at least 1 week after insertion of the gold
markers.
The 3-year LC and OS were 81% and 68%, especially
in patients with T1a tumor, the 3-year LC and OS was
92% and 83% in the present study. These were equiva-
lent to several studies of SBRT for Stage I NSCLC shown
in Table 4 [2,8,10,21,30-34]. However, it is lower than
those reported by Timmerman et al., who showed a
higher 3-year LC of 97.6% after administering a highernt and planning target volume (PTV), (b) Correlation with
), (c) Correlation with maximum amplitude of marker movement
Table 4 Studies of stereotactic body radiotherapy for stage I non-small cell lung cancer
Author Dose* median follow-up 3yLC 3yOS
(reference) n (Gy) (mo) (%) (%)
Onishi (2) 257 30-84(i) 38 NA 57
Timmerman (8) 55 54(p) 34 98 56
Nagata (10) 42 48(i) 30 NA 83 (T1 only)
Onimaru (21) 41 40-48(i) 27 57 47
Uematsu (30) 50 40-60(i) 60 NA 66
Koto (31) 31 45-60(i) 32 78 72
Nyman (32) 45 45(p) 43 80 55
Takeda (33) 38 50(p) 31 93 (T1 only) 90 (T1 only)
Taremi (34) 108 48-60(p) 19 89 (4y) 30 (4y)
Current study 109 48(i) or 40(p) 25 81 68
*Dose was prescribed at the isocenter (i) or periphery (p) of the tumor.
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were 78% and 64% in patients with Stage I NSCLC and
the 5-year LC and OS was 83% and 75% in patients with
T1a tumor in the present study. Asamura et al. and
Naruke et al. reported that the 5-year OS was 77.3% and
70.8% for patients with clinical stage IA (T1 tumor) and
was 83.9% and 79.0% for patients with pathological stage
IA [35,36]. They did not perform FDG-PET at clinical sta-
ging, therefore, clinical stage might be underestimated.
Our data are compatible with surgical series although
phase III comparison is required to prove it.
It was very difficult in distinguishing radiation pneu-
monitis/fibrosis with local recurrence. Local disease re-
currence was considered to have occurred only when
enlargement of the local tumor continued for > 6 months
on follow-up CT scans. FDG-PET and/or histologic con-
firmation was recommended when local recurrence was
suspected. We considered that tumor enlargement only
for 3 months might be false positive for local recurrence.
In our experience, six months or larger period were
thought to be suitable for judgment of the local recur-
rence. The definition of local control was uncertain in
radiotherapy compared with surgical resection.
Matsuo et al. reported that tumor diameter and sex
were the most significant prognostic factors in SBRT for
NSCLC [11]. In this study, multivariate analysis demon-
strated that only the tumor diameter ( ≤ / > 2 cm) was a
significant factor in OS. Li et al. reported that FDG-PET
/CT was specific in N0 staging for T1–2 NSCLC and
the negative predictive value was about 91% in clinical
N0 patients, suggested that FDG-PET/CT may help to
accurately stage N0 patients and thus identify patients
for SBRT [37]. However, there was no statistical signifi-
cant difference in OS between patients underwent FDG-
PET scan before SBRT and those did not in this study.
Grade 3 RP occurred in 2.8% of cases in the present
study. The incidence of Grade 3 or greater RP in literaturedistributed from 0% to 4.9% for patients with stage I
NSCLC [2,10,21,31,38]. The severity and incidence of RP
in the present study in the present was similar to previous
SBRT studies using a similar dose. Timmerman et al.
reported a higher incidence of Grade 3 or higher-grade RP
of 16.4% with a higher 3-year LC of 97.6% after adminis-
tering a higher dose of 54 Gy in 3 fractions [8]. The
present results indicate that when using SBRT with RTRT
the dose to the target may be able to be increased from
48 Gy in 4 fractions to a higher dose such as 54 Gy in 3
fractions and the LC could be improved with a reduction
in the incidence of Grade 3 or higher-grade RP. Since the
incidence of RP in other SBRT studies is so low, it is not
certain yet whether RTRT is any better than other SBRT
technology for reducing the incidence of RP by means of a
higher dose.
MLD and V20 of the lung volume minus target vo-
lume were reported as risk factors of RP [39-43]. Palma
et al. also reported that predictors of fatal pneumonitis
were daily dose > 2 Gy, V20, and lower lobe tumor loca-
tion [38]. Comparing non-gated radiotherapy which in-
cludes the range of motion adding to CTV to create
PTV, the size of PTV is smaller in gated radiotherapy
using RTRT in principle irrespective of the tumor ampli-
tude and tumor location. Consequently, MLD and V20
of the lung volume minus PTV should be smaller in the
gated radiotherapy using RTRT. Barriger et al. reported
that median MLD and V20 were 4.1 Gy and 4% for
patients with NSCLC treated by SBRT, respectively [43].
They also reported that median MLD was 5 Gy in pa-
tients with RP Grade 2–4, compared with 4 Gy in those
with RP Grade 0/1, and median V20 was 6.6% in pa-
tients with RP Grade 2–4, compared with 4% in those
with RP Grade 0/1, respectively, which were similar to
our present study. In the present study, although the
maximum amplitude of the marker movement of the
lower lobe was significantly greater than that of upper
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amplitude of marker movement and larger PTV, MLD,
or V20. Present study suggested that SBRT with gated
radiotherapy using RTRT system was effective to reduce
MLD and V20 and thus the risk of RP consequently.
In this study, we showed the clinical outcomes of
SBRT using RTRT for Stage I NSCLC and found that
there was no correlation between larger maximum amp-
litude of marker movement and larger PTV, MLD, or
V20. These are risk factors of RP; therefore, RTRT is
thought to be useful especially in cases of large ampli-
tude of tumor movement.Conclusions
Using only a 5-mm PTV margin to CTV without add-
itional margin for organ motion, SBRT using the RTRT
system achieved LC and OS comparable to other SBRT
series with very low incidence of RP, which was consis-
tent with the small MLD and V20 irrespective of the
tumor amplitude. For stage-I NSCLC, SBRT using RTRT
was suggested to be reliable and effective, especially for
patients with large amplitude of tumor movement.
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